Checkpoint Therapeutics (NASDAQ:CKPT) just reported results for the second quarter of 2024.
- Checkpoint Therapeutics reported earnings per share of -18 cents. This was above the analyst estimate for EPS of -30 cents.
- The company reported revenue of $41,000.
- This was 105% better than the analyst estimate for revenue of $20,000.